Neumora Therapeutics shares are trading lower after the company reported pre-clinical toxicology results from NMRA-215. The company conducted a repeat 13-week toxicology study after an audit revealed various discrepancies resulting in several critical audit observations.

Neumora Therapeutics Q2 EPS $(0.23) Beats $(0.24) Estimate

Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 30.3 percent increase over losses of $(0.33) per share

8-K filing — Neumora Therapeutics, Inc. (NMRA)

Filed: 2026-08-14 AccNo: 0001193125-26-350349 Size: 345 KB Item 2.02: Results of Operations and Financial Condition Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

Why Is BioAge Labs Stock Sinking Friday?

BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concerns for NLRP3-targeting therapies.

Neumora Therapeutics shares are trading lower amid possible sympathy with Novo Nordisk after its ZEUS phase 3 trial did not translate into a MACE risk reduction.